Disclaimer

This material contains forward-looking statements with respect to the company's outlook regarding drivers, developments, and trends affecting its worldwide markets, opening of international offices, new product development and commercial launch dates, projected revenues, net income margins, earnings per share, revenue growth targets, net income growth targets, sales force and distributor targets, projections of the size of China's healthcare market, estimated government expenditures, research and development expenditure targets, the company's manufacturing development plan, and the anticipated results of its product development activities. These statements are based on information available at the time they are made and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond the company's control. Factors that affect the Company's business operations and product development, as well as a further list and description of risks and uncertainties associated with Mindray's business, are discussed in its reports filed with the Securities and Exchange Commission, including its most recent annual report on Form 20-F. Mindray disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Mission and Vision

**MISSION**
To improve the health and well-being of the world’s people by providing the **highest quality medical equipment and services** at the most competitive prices

**VISION**
To be a **world-class medical equipment solutions provider** by increasing accessibility to affordable quality health care while creating value for customers, employees, shareholders and society
Investment Highlights

- **World-class R&D platform**
  - Industry’s largest R&D team in China with 1,400+ staff
  - Two research centers in Mahwah and Seattle, USA, with 80+ staff

- **Competitive product positioning**
  - Top quality and best value in the market

- **Comprehensive sales & service infrastructure in China**
  - 1,000+ sales and sales support staff in 29 offices covering major cities all over China
  - 2,000+ distributors including 1,200+ exclusive distributors

- **Established and fast growing international presence**
  - Acquired established direct sales & services infrastructure in U.S. & W. Europe
  - 170+ sales countries and 1,200+ distributors

- **Experienced management team**
  - Co-founders are pioneers in China’s medical device industry
  - International experience

- **Healthy cash flow and strong cash position**
Product Line I: Patient Monitoring & Life Support Products

- 35+ models currently
- Multi-parameter Patient Monitoring
- Hand-carried Patient Monitoring
- Central Station
- Telemetry
- Anesthesia Machine
- Defibrillator
- Surgical light & bed
The 3rd Largest Player in the Global Patient Monitoring Devices Market

- **Global PMD market is ~$ 2.7 billion, projected to grow at 3% annually**
  - In China, Mindray holds ~47% market share for the PMD market as of December 2008
  - Overall PMD market in China is ~$170mm and growing at more than 8% per annum

- **Main growth drivers**
  - Penetrating into higher end hospitals
  - Increasing use of PMDs in hospitals in China
  - Ongoing replacement of old/expiring PMDs worldwide
  - Operating room full suite solution

Source: company estimates
Product Line II: In-vitro Diagnostic Products

- 10+ models currently
- 3-part/5-part Hematology Analyzer
- Biochemistry Analyzer
- Microplate Washer
- Microplate Reader
- Reagents
In-Vitro Diagnostic Products, the Biggest Addressable Market

- Global market for in-vitro diagnostic devices ("IVD") is ~$18.8 billion, projected to grow at 4% annually
  - In China, Mindray has ~44% of the 3-part hematology analyzers market, 17% of the biochemistry analyzers market as of December 2008
  - Overall IVD market in China is ~ $870mm and expected to grow at 11% per annum for the next 5 years

- Growth drivers
  - Preventive measures
    - Demand for early and better diagnostics
  - Government funding to hospitals and clinics in rural areas in China
  - Accelerating reagent business

Source: company estimates

Product Development Roadmap

- Immunoassay & reagent: 10.5B
- 5-Part Hematology & reagent: 1.1B
- Biochemistry & reagent: 5.7B
- 3-Part Hematology & reagent: 1.5B

- 55 hematology reagents and 55 biochemistry reagents
- Total addressable market size worldwide: ~ USD18.8bln
Product Line III: Medical Imaging Systems

- 10+ models currently
- B/W Ultrasound
- Color Ultrasound
- Portable B/W Ultrasound
- Hand-carried Color Ultrasound
- Digital Radiography

NEW!
Medical Imaging Systems, the Fastest Growing Line

- Global ultrasound market is ~ $4.5 billion, projected to grow at 4% annually
  - In China, Mindray has ~32% of the b/w ultrasound market, 8% of the color ultrasound market as of December 2008
  - Chinese ultrasound market ~ $589mm, expected to grow at more than 13% over the next few years

- Growth drivers
  - Government funding to hospitals, clinics in rural areas as well as community clinics
  - Ongoing replacement of old or expiring black & white ultrasounds
  - Hand-carried ultrasound (“HCU”) expected to outpace overall market

Source: company estimates
Growth Driver - R&D Competency

Global R&D Headcount

- Overall R&D
- PMD
- IVD
- MIS
- Others

Shenzhen R&D Structure

- Degree
  - Others 6%
  - PhD 3%
  - Bachelor 28%
  - Master 63%

- Functionality
  - Others 24%
  - Software 24%
  - Hardware 12%
  - System 26%
  - Mechanic 14%

Total: 1,420 Engineers

R&D Investment

- (US$mm)
- % of sales (%)

Patents

- Authorized (in China): 350
- Pending (in China): 398
- Authorized (ex-China): 20
- Pending (ex-China): 134

Note: As of Dec. 31, 2008

Note: As of Jun. 30, 2009
10 First-time Product Approvals in 2008

Patient Monitoring & Life Support Products
- iPM Monitor (Dec. 2008)
- Defibrillator (Dec. 2008)
- AS3000 (Jun. 2008)
- EX55/65 (Mar. 2008)

In-Vitro Diagnostic Products
- BC-5300/5380 5-Part Hematology Analyzer (Jan. 2008)
- BS-380 Biochemistry Analyzer (Dec. 2008)
- BA88A semi-automatic biochemistry analyzer (Oct. 2008)
- 6 Biochemistry reagents & 6 Hematology reagents (FY 2008)

Medical Imaging Systems
- DC-3 Ultrasound (Mar. 2008)
- DigiEye-560T Digital Radiography (Jun. 2008)
- DigiEye-561T (Dec. 2008)
Product Pipeline in 2009

Patient Monitoring & Life Support Products

✓ Surgical light (Mar. 2009)
✓ Surgical bed (Mar. 2009)
✓ WATO EX 20/30/35 (2H2009)
✓ Accutorr V (Feb. 2009)

In-Vitro Diagnostic Products

■ 6 reagents (2H2009)

Medical Imaging Systems

✓ DC-7 4D-Ultrasound (1H2009)
✓ DP6900 Portable b/w ultrasound (Mar. 2009)
■ DigiEye-760T Digital Radiography (1H2009)

Another jointly-developed patient monitoring device (2H2009)
## 2008 Results Highlights

<table>
<thead>
<tr>
<th>USD (in millions)</th>
<th>FY 2008</th>
<th>FY 2007</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>except EPS, A/R, A/P, Inventory days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Revenues</td>
<td>547.5</td>
<td>294.3</td>
<td>86.0%</td>
</tr>
<tr>
<td>Operating Income(^1)</td>
<td>117.5</td>
<td>80.0</td>
<td>46.9%</td>
</tr>
<tr>
<td>Non-GAAP OI</td>
<td>144.5</td>
<td>90.2</td>
<td>60.2%</td>
</tr>
<tr>
<td>Net Income(^1)</td>
<td>108.7</td>
<td>78.0</td>
<td>39.3%</td>
</tr>
<tr>
<td>Non-GAAP NI</td>
<td>132.7</td>
<td>88.6</td>
<td>49.7%</td>
</tr>
<tr>
<td>Diluted EPS(^1)</td>
<td>0.96</td>
<td>0.69</td>
<td>38.4%</td>
</tr>
<tr>
<td>Non-GAAP Diluted EPS</td>
<td>1.17</td>
<td>0.79</td>
<td>48.8%</td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>96.4</td>
<td>189.0</td>
<td></td>
</tr>
<tr>
<td>Restricted cash – short-term(^2)</td>
<td>119.7</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Short-term investments(^2)</td>
<td>36.8</td>
<td>55.9</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) GAAP figures including impact from non-cash, share-based compensation expense, acquired inventory fair value adjustments, acquired intangible assets amortization expense, in-progress research and development (IPR&D), and restructuring charges

\(^2\) Restricted based on the security package required for the bank loans as of December 31, 2008. Use of such funds are permitted provided that the proportionate amount of debt must be retired concurrently. As of December 31, 2008, the short-term bank loans can be fully repaid from such short-term restricted cash and short-term investments.
Financials – 2Q09 Results Highlights

USD (in millions)  

<table>
<thead>
<tr>
<th></th>
<th>2Q09</th>
<th>2Q08</th>
<th>1Q09</th>
<th>YoY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Revenues</td>
<td>160.1</td>
<td>145.7</td>
<td>134.2</td>
<td>9.9%</td>
</tr>
<tr>
<td>Operating Income¹</td>
<td>39.0</td>
<td>27.8</td>
<td>29.4</td>
<td>40.2%</td>
</tr>
<tr>
<td>Non-GAAP OI</td>
<td>43.9</td>
<td>40.0</td>
<td>34.7</td>
<td>9.8%</td>
</tr>
<tr>
<td>EBITDA</td>
<td>46.7</td>
<td>33.6</td>
<td>35.6</td>
<td>38.8%</td>
</tr>
<tr>
<td>Net Income¹</td>
<td>33.0</td>
<td>24.1</td>
<td>25.3</td>
<td>37.2%</td>
</tr>
<tr>
<td>Non-GAAP NI</td>
<td>37.8</td>
<td>35.2</td>
<td>30.5</td>
<td>7.5%</td>
</tr>
<tr>
<td>Diluted EPS¹</td>
<td>0.29</td>
<td>0.21</td>
<td>0.23</td>
<td>38.8%</td>
</tr>
<tr>
<td>Non-GAAP Diluted EPS</td>
<td>0.34</td>
<td>0.31</td>
<td>0.27</td>
<td>8.7%</td>
</tr>
<tr>
<td>Accounts Receivable Days</td>
<td>54</td>
<td>32</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Inventory Days</td>
<td>82</td>
<td>57</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Accounts Payable Days</td>
<td>59</td>
<td>50</td>
<td>58</td>
<td></td>
</tr>
</tbody>
</table>

Note:

¹ GAAP figures include share-based compensation expense, acquired intangible assets amortization expense, in process research & development and termination payments

Financial results include the results of operations of the patient monitoring business acquired from Datascope starting from May 1, 2008
Growth Drivers and Strategy in China

- Gain market share in high-end markets
- Target rural area hospitals and urban community clinics in major cities and benefit from government’s significant investment in these low-end markets
- Introduce new products to penetrate new markets; recent examples include: Beneview series, color ultrasound, 5 part hematology, digital radiography, defibrillator and anesthesia machines
- Generate more recurring revenue from reagents
  - Increase installation base of 5-part hematology analyzers
  - More biochemistry reagents to launch into market
- Enhance brand recognition in big hospitals of major cities
- Government providing support for the marketplace
Strengths and Growth Drivers in International Market

- Building up worldwide distribution networks
  - 400+ international sales people work together with 1,900+ international distributors
  - Established operations in 12 strategic sales countries with continuous recruitment and localization of staff to increase awareness of the Mindray brand
  - Realigned sales channels to maximize DPM’s direct sales infrastructure in the U.S. and Western Europe and Mindray’s emerging market presence
  - Leverage DPM’s long standing contractual relationships with all major GPOs in the U.S.

- Expand Market Opportunity and increase share in current market environment
  - MR’s high value-price ratio products are more attractive in a more cost-conscious global market
  - Launched first jointly developed product – Accutorr V in 1Q09, expected to launch 2nd in 2H09
  - Expanded product portfolio in existing and new market segments increases total market opportunity

- Continuing to benefit from long-term global trends
  - Government policies to increase access to healthcare for uninsured
  - Higher focus on healthcare affordability
  - Aging population
Mindray’s mission to provide high-quality medical devices at competitive prices has delivered high-growth in both developed and developing markets.

Pragmatic positioning in each market and segment optimizes earnings by striking a balance between profit and market share.

World-class R&D capabilities and operational efficiencies ensure quality consistency, pricing competency and abundant cash flow.

Acquisition of DPM adds highly complementary assets to Mindray, including a recognized global brand and direct sales & service infrastructure in U.S. and W. Europe.

Closely monitoring the development of various healthcare reform proposals as well as the impact of the on-going world economic crisis.
Appendix
Focus on Maximizing Shareholder Value

Net Income¹

(US$mm)

<table>
<thead>
<tr>
<th>Year</th>
<th>Net Income</th>
<th>Net Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>13</td>
<td>22.0%</td>
</tr>
<tr>
<td>2004</td>
<td>23</td>
<td>26.0%</td>
</tr>
<tr>
<td>2005</td>
<td>35</td>
<td>25.6%</td>
</tr>
<tr>
<td>2006</td>
<td>53</td>
<td>27.5%</td>
</tr>
<tr>
<td>2007</td>
<td>89</td>
<td>30.1%</td>
</tr>
<tr>
<td>2008</td>
<td>133</td>
<td>24.2%</td>
</tr>
</tbody>
</table>

CAGR = 59.2%

EPS¹

(US$)

<table>
<thead>
<tr>
<th>Year</th>
<th>EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>0.15</td>
</tr>
<tr>
<td>2004</td>
<td>0.27</td>
</tr>
<tr>
<td>2005</td>
<td>0.42</td>
</tr>
<tr>
<td>2006</td>
<td>0.55</td>
</tr>
<tr>
<td>2007</td>
<td>0.79</td>
</tr>
<tr>
<td>2008</td>
<td>1.17</td>
</tr>
</tbody>
</table>

¹ Non-GAAP numbers are excluding impact from non-cash, share-based compensation expense, acquired inventory fair value adjustments, acquired intangible assets amortization expense, in-progress research and development (IPR&D), and restructuring charges
Revenue Breakdown by Region

2007 Total Revenues: US$294 mm
- Emerging Market: 22%
- Developed Market: 15%
- Others: 14%
- China: 49%

2008 Total Revenues: US$548 mm
- Emerging Market: 19%
- Developed Market: 27%
- Others: 12%
- China: 42%

Rapidly Expanding International Presence
**Growth Catalysts in China---Macro Environment**

**Chinese public health market**

**Forecast incremental demand by 2020**

By 2020 $US776 bn of incremental demand will come from China.

**Healthcare expenditures as % GDP**

Source: China Statistical Yearbook 2006, Bear Sterns Asia Ltd. estimates

Source: Goldman Sachs Research 2006, Gao Hua Securities Research estimates

Leading Market Positions in China

**Patient Monitoring Devices**
- Foreign brands: 34%
- Mindray: 49%
- Other domestic brands: 17%

**200~400 T/H Biochemistry Analyzers**
- Foreign brands: 46%
- Mindray: 30%
- Other domestic brands: 24%

**3-Part Hematology Analyzers & Reagents**
- Foreign brands: 22%
- Mindray: 39%
- Other domestic brands: 39%

**B/W Ultrasound Systems**
- Foreign brands: 24%
- Mindray: 32%
- Other domestic brands: 44%

Note: 1H09 domestic China market share numbers, corporate estimates as of June 30, 2009
Promising Market Expansion Potential

### In-Vitro Diagnostic Products & Reagents
- Foreign brands 50%
- Mindray 16%
- Other domestic brands 34%

RMB 2,015mm

### Patient Monitoring & Anesthesia Machines
- Foreign brands 42%
- Mindray 37%
- Other domestic brands 21%

RMB 879mm

### Ultrasound Systems (B/W & Color Ultrasound Systems)
- Foreign brands 73%
- Mindray 13%
- Other domestic brands 14%

RMB 2,081mm

### Life Support Products (Defibrillators, Surgical Lights & Beds)
- Foreign brands 70%
- Domestic brands 30%

Est. RMB 800mm

Note: 1H09 domestic China market share numbers, corporate estimates as of June 30, 2009